Abstract
Background: We aimed to study the relationships between serum Trimethylamine N-oxide (TMAO) and L-carnitine levels with metabolic syndrome profiles, including obesity, blood pressure, serum lipids, serum glucose and insulin resistance (IR)-related index in humans.
Methods: Cross-sectional study was performed in 1,081 subjects from the CODING study in Newfoundland. Serum TMAO and L-carnitine levels were quantified by LC-MS/MS. Metabolic markers were measured in all subjects using fasting blood samples. Partial correlation and linear regression analysis were employed after systematically controlling the major confounding factors, such as age, gender, calorie intake and physical activity level.
Results: Serum L-carnitine level was positively correlated with serum triglyceride (TG), serum insulin, IR in males with normal fasting glucose (p < 0.05 for all) and positively correlated with only serum TG (p < 0.05) in those with hyperglycemia. In females, significant positive correlations were identified between serum L-carnitine level with obesity, serum total cholesterol, glucose, insulin, and IR in those with normal fasting glucose level (p < 0.05 for all), while none was found in those with hyperglycemia. Serum TMAO level was only identified to be positively correlated with serum insulin level and IR in hyperglycemic males (p < 0.05 for all).
Conclusions: Serum L-carnitine level was significantly associated with an unfavorable metabolic syndrome (MS) profile mainly in subjects with normal serum glucose level, while serum TMAO level was associated with an unfavorable MS profile in subjects with hyperglycemia. The gender difference warrants further investigations.
Keywords: L-carnitine, TMAO, metabolic syndrome, insulin resistance, cross-sectional
Introduction
Trimethylamine N-oxide (TMAO) is a product of trimethylamine (TMA) oxidation. Recently, TMAO has been recognized as a novel risk factor for cardiovascular diseases and reported to be elevated in several cardiovascular events and type 2 diabetes mellitus (T2DM) (1, 2). In humans, TMAO is acquired from either direct uptake from TMAO containing foods, especially seafood, or in vivo production from its metabolic precursors, like L-carnitine, choline, and betaine (1). L-carnitine is an essential nutrient involved in lipid metabolism, which can be biosynthesized from amino acids, specifically L-lysine and L-methionine, or directly obtained from foods, such as beef, lamb, fish, poultry and milk (3). As an important precursor for TMAO, dietary L-carnitine can be metabolized by gut bacteria to release TMA, which is subsequently oxidized in the liver by flavin-containing monooxygenase 3 to form TMAO (4).
Metabolic syndrome (MS) is defined by a constellation of multiple risk factors for T2DM and cardiovascular disease (CVD), including hyperglycemia, dyslipidemia, obesity, hypertension and impaired insulin sensitivity (5). Currently, MS affects ~30% of individuals across the world and has become one of the major worldwide public-health challenges (6). The mechanism of MS is not clear yet but insulin resistance (IR) and obesity may play critical roles (7). Evidence for an effect of TMAO and L-carnitine on MS can be found in both animals and humans. TMAO was first reported to be harmful to human health in 2011 (8). Wang et al. found that serum TMAO level was positively related with the risk of CVD in humans and proved that dietary TMAO supplementation promoted atherosclerosis in mice (8). Subsequent studies confirmed that serum TMAO levels positively correlated with CVD events (9). Other studies also proved that serum TMAO levels were elevated in T2DM patients (10). In a previous study, we found that dietary TMAO exacerbated IR in high fat diet-fed obese mice (11). A recent cross-sectional study in 300 patients with increased cardiovascular risk indicated that serum TMAO level was positively correlated with IR (12). L-carnitine, which can be metabolized to TMA, is a primary metabolic precursor for TMAO. Dietary L-carnitine supplementation can significantly increase serum TMAO levels in both human and rodents (4, 13). Oral L-carnitine treatment could also promote atherosclerosis in ApoE knockout mice (10). L-carnitine is well-known as a critical long fatty acid transport facilitator involved in lipid metabolism, especially fatty acid oxidation. Numerous studies in both humans and animals also show that dietary L-carnitine could notably reduce body weight and improve serum lipid profiles (14, 15). Serum L-carnitine levels are significantly lower in obese pregnant women (16). L-carnitine can also alleviate IR in high fructose-fed rodents (17), while evidence of the same in humans is lacking. Collectively, these reports indicate a potential relationship between serum TMAO and L-carnitine levels with MS and its risk factors. Moreover, due to the production of TMAO, the beneficial effect of L-carnitine on health is controversial.
To our knowledge, no previous study has systematically examined the relationships of serum TMAO or L-carnitine level with MS components in humans. To fill this knowledge gap, the present cross-sectional study was performed to clarify the association of serum TMAO and L-carnitine levels with MS related risk factors, including obesity, serum lipids, serum glucose, blood pressure, and IR-related index in Newfoundland population. Our findings provide new insights into the relationships between TMAO and its metabolic precursors in human health.
Materials and Methods
Study Population
One thousand and eighty-one subjects from the CODING study in the Newfoundland province of Canada were enrolled (18, 19).
This study was carried out in accordance with the recommendations of the Health Research Ethics Authority (HREA), Memorial University, St. John's, NL, Canada, with Project Identification Code #10.33 (latest date of approval: 11 February 2016) with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the HREA (20, 21).
Anthropometric Measurements
After a 12-h fast, anthropometrics measurements were examined. Body weight, height, waist circumference (WC) and hip circumference of the participants were measured as described previously (20). Waist-to-hip ratio (WHR) was calculated by division of WC by hip circumference. BMI (kg/m2) was also calculated. Blood pressure of the subjects was measured by Dinamap 845 XT equipment after 10 min of resting.
Lifestyle and Dietary Intake Assessment
Subjects' lifestyle-related information were collected with self-administered screening questionnaires, involving age, gender, and family origin, disease status, medicine use, alcohol consumption, smoking status, and menopausal status (for women only). Physical activity level was assessed by an ARIC Baecke Questionnaire (21).
Dietary intake was measured by a semi-quantitative Willett Food Frequency Questionnaire (FFQ) and a NutriBase Clinical Nutrition Manager software was used to obtain the total daily calorie intake (22).
Biochemical Measurements
Venous blood samples were collected and serum samples were separated. Serum concentrations of glucose, triglycerides (TG), total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-c) were detected on an Architech C16000 clinical chemistry analyzer (Abbott Laboratories, IL, USA). Low-density lipoprotein cholesterol (LDL-c) and atherogenic index (AI) were calculated by: LDL-c = TC - HDL-c - TG/2.2 and AI = (TC − HDL-c)/HDL-c (23), respectively. An Architect I2000 immunoassay analyzer was used to determine fasting insulin (FINS) level. IR and β cell function were assessed with homeostasis model assessment (HOMA) (24):
HOMA-IR = (Fasting Insulin [mU/L] × Fasting Glucose [mmol/L])/22.5
HOMA- β = (20 × Fasting Insulin [mU/L])/(Fasting Glucose [mmol/L] -3.5)
Quantitative insulin-sensitivity check index (QUICKI) was also calculated (25):
QUICKI = 1/[log (fasting insulin (mU/L)) + log (fasting plasma glucose (mmol/L) × 18.0182)].
Serum TMAO and L-Carnitine Levels Measurements
Levels of serum TMAO and L-carnitine were detected by liquid chromatography with tandem mass spectrometry (LC/MS/MS). Detailed methods were described in our previous publication (26). Briefly, protein-free serum enriched with d9-TMAO and d11-L-carnitine (Cambridge Isotopes, Tewksbury, MA, USA) was injected into a normal-phase Atlantis HILIC Silica HPLC column (3 μM, 2.1 × 100 mm, Waters Corporation, Milford, MA). TMAO and L-carnitine were eluted in an isocratic solvent system consisting of 25% ammonium formate (15 mM, pH 3.0) and 75% acetonitrile and delivered to the tandem Micromass Ultima Triple-Quad mass spectrometer (Waters Corporation, Milford, MA). The m/z transitions during mass spectrometry were: d9-TMAO 85>68, TMAO 76>58, d11-L-carnitine 171.1>103, L-carnitine 162>103.
Data Analysis
All data are presented as means ± SD (standard deviation). To normalize the data distributions, serum TMAO, fasting insulin, fasting glucose, serum TG, HOMA-IR, HOMA-β, and total calorie intake were log-transformed. Differences in measurements between women and men were detected by independent Student's t-test.
Pearson correlation analysis was performed to find potential confounding factors by studying the associations with MS profiles and serum TMAO or L-carnitine levels. Analysis of covariance (ANCOVA) were used to study the statistical interaction between serum TMAO, L-carnitine levels, and sex on the main outcomes. Partial correlation analysis was performed to evaluate the relationships of serum TMAO and L-carnitine levels with MS related indexes, including obesity, blood pressure, serum lipids levels, and IR related indexes within male and female groups. Age, total calorie intake, physical activity level, medicine status, alcohol intake, smoking status, and menopausal status (for females) were controlled during the analysis. Stepwise multiple linear regression analysis was performed to test the contribution of serum TMAO, L-carnitine levels to MS related components among women or men. MS-related components were used as dependent variables. Serum TMAO, L-carnitine levels and all the confounding factors were used as independent variables.
To further explore the associations between serum TMAO or L-carnitine levels with MS related components in different metabolic sub-groups, subjects were divided into normal or high serum glucose level groups based on the criteria of National Cholesterol Education Program (NCEP)-ATP III with fasting glucose ≥ 5.6 mmol/L recognized as hyperglycemia (27). Partial correlation analysis and stepwise multiple linear regression analysis were used to determine the correlations between serum TMAO and L-carnitine levels with MS profiles.
A SPSS 20.0 (SPSS Inc., Chicago, IL) software was used to assess all the statistical analyses. P < 0.05 was considered as statistically significant and all the tests were two sided.
Results
Demographic Parameters and Serum L-Carnitine, TMAO Levels
As shown in Table 1, male subjects were 2.7 years younger than female subjects (p < 0.001). Obesity measures, systolic pressure, diastolic pressure, physical activity level and dietary calorie intake were higher in males (p < 0.001 for all). For serum parameters, males had higher fasting TG and glucose levels, but lower serum HDL-c levels (p < 0.001 for all). Atherogenic index (AI), HOMA-IR index and HOMA-β index were dramatically lower, while QUICKI index was higher in females (p < 0.01 for all). Male subjects had significantly higher serum L-carnitine level (p < 0.001). No notable differences were found in hip circumference, serum TC, LDL-c, insulin, and TMAO levels between genders.
Table 1.
Characteristics of the participants by gender.
| Male (536) | Female (545) | P | |
|---|---|---|---|
| Mean ± SD | Mean ± SD | ||
| Age | 42.21 ± 13.26 | 44.90+11.3 | 0.000 |
| Weight (kg) | 88.20 ± 15.67 | 70.3+13.2 | 0.000 |
| BMI | 28.27 ± 4.58 | 26.7+5.0 | 0.000 |
| Waist circumference (cm) | 99.45 ± 12.64 | 91.25+13.59 | 0.000 |
| Hip (cm) | 101.28 ± 9.94 | 102.53+11.42 | 0.055 |
| Waist/Hip Ratio | 0.98 ± 0.06 | 0.89 ± 0.07 | 0.000 |
| Systolic pressure (mmHg) | 132.66 ± 14.84 | 122.51 ± 16.14 | 0.000 |
| Diastolic pressure (mmHg) | 84.12 ± 10.17 | 80.42 ± 10.97 | 0.000 |
| Physical activity level | 8.37 ± 1.56 | 7.99 ± 1.49 | 0.000 |
| Dietary calorie intake (kcal/day) | 2201 ± 1021 | 1823 ± 787 | 0.000 |
| Serum TG (mmol/L) | 1.48 ± 0.99 | 1.17 ± 0.68 | 0.000 |
| Serum TC (mmol/L) | 5.08 ± 1.08 | 5.16 ± 0.97 | 0.199 |
| Serum HDL-c (mmol/L) | 1.19 ± 0.28 | 1.52 ± 0.38 | 0.000 |
| Serum LDL-c (mmol/L) | 3.22 ± 0.91 | 3.11 ± 0.90 | 0.057 |
| Atherogenic index (AI) | 4.42 ± 1.22 | 3.55 ± 0.97 | 0.000 |
| Serum glucose (mmol/L) | 5.32 ± 0.67 | 5.1 ± 0.67 | 0.000 |
| Serum insulin (mU/L) | 10.46 ± 7.06 | 9.66 ± 5.92 | 0.142 |
| HOMA-IR | 2.51 ± 1.81 | 2.24 ± 1.61 | 0.006 |
| HOMA–β | 399.11 ± 350.98 | 331.4 ± 339.1 | 0.000 |
| QUICKI | 0.35 ± 0.03 | 0.36 ± 0.032 | 0.009 |
| Serum L-carnitine (μmol/L) | 42.71 ± 9.85 | 36.77 ± 9.34 | 0.000 |
| Serum TMAO (μmol/L) | 6.15 ± 9.34 | 5.43 ± 7.09 | 0.177 |
All values are mean ± SDs. BMI, body mass index; WC, waist circumference. Significant differences between female and male group, based on independence sample Student's t-test, Statistical significance was set to p < 0.05.
Correlation Between Serum L-Carnitine, TMAO Levels, and MS Related Indexes by Gender
The associations between serum L-carnitine and TMAO levels with MS related indexes in males and females after adjusting for confounding factors are presented in Table 2. In males, serum L-carnitine level was positively correlated with serum TG level (r = 0.139, p < 0.01), serum insulin level (r = 0.111, p < 0.05), HOMA-IR (r = 0.101, p < 0.05) and negatively correlated with QUICKI index (r = −0.104, p < 0.05). In females, serum L-carnitine level was positively correlated with weight (r = 0.186, P < 0.001), BMI (r = 0.178, P < 0.000), waist (r = 0.134, P < 0.01), hip (r = 0.171, P < 0.001), serum TC (r = 0.091, p < 0.05), glucose (r = 0.094, p < 0.05), insulin levels (r = 0.137, p < 0.01), HOMA-IR index (r = 0.143, p < 0.01), HOMA-β index (r = 0.134, p < 0.01), and negatively correlated with QUICKI index (r = −0.147, p < 0.001). No significant relationships were found between serum TMAO level and MS related risk factors.
Table 2.
Partial correlations between serum L-carnitine, TMAO levels with components of MS in females and males.
| Male | Female | |||
|---|---|---|---|---|
| r1(P) | r2(P) | r1(P) | r3(P) | |
| L-CARNITINE (μmol/L) | ||||
| Weight | 0.019(0.652) | 0.001(0.987) | 0.197(0.000) | 0.186(0.000) |
| BMI | 0.062(0.152) | 0.024(0.588) | 0.225(0.000) | 0.178(0.000) |
| Waist circumference | 0.065(0.135) | 0.007(0.866) | 0.224(0.000) | 0.134(0.002) |
| Hip circumference | 0.081(0.060) | 0.032(0.466) | 0.239(0.000) | 0.171(0.000) |
| Waist/hip ratio | 0.009(0.828) | −0.031(0.473) | 0.086(0.044) | 0.005(0.903) |
| Systolic BP | 0.071 (0.100) | 0.041(0.351) | 0.111(0.010) | 0.039(0.374) |
| Diastolic BP | 0.029 (0.501) | −0.017(0.697) | 0.089(0.038) | 0.036(0.407) |
| Serum TG | 0.179 (0.000) | 0.139(0.001) | 0.122 (0.004) | 0.039(0.369) |
| Serum TC | 0.100 (0.020) | 0.068(0.119) | 0.193 (0.000) | 0.091(0.036) |
| Serum HDL-c | −0.013 (0.759) | −0.007(0.878) | −0.038(0.375) | 0.028(0.523) |
| Serum LDL-c | 0.038 (0.386) | 0.015(0.736) | 0.176 (0.000) | 0.059(0.171) |
| Atherogenic index (AI) | 0.057 (0.190) | 0.022(0.614) | 0.139 (0.001) | −0.029(0.498) |
| Serum glucose | 0.046 (0.291) | −0.022(0.614) | 0.221 (0.000) | 0.094(0.030) |
| Serum insulin | 0.159 (0.000) | 0.111(0.011) | 0.155 (0.000) | 0.137(0.002) |
| HOMA-IR | 0.157 (0.000) | 0.101(0.020) | 0.185 (0.000) | 0.143(0.001) |
| HOMA-β | 0.147(0.001) | 0.081(0.065) | 0.216(0.000) | 0.134(0.002) |
| QUICKI | −0.161 (0.000) | −0.104(0.017) | −0.185 (0.000) | −0.147(0.001) |
| TMAO (μmol/L) | ||||
| Weight | −0.050(0.247) | −0.056(0.202) | 0.052(0.229) | 0.032(0.456) |
| BMI | −0.033(0.453) | −0.065(0.136) | 0.033(0.447) | −0.012(0.779) |
| Waist circumference | 0.003(0.951) | −0.052(0.230) | 0.067(0.121) | −0.009(0.827) |
| Hip circumference | 0.011(0.798) | −0.031(0.471) | 0.054(0.213) | −0.003(0.945) |
| Waist/hip ratio | −0.005(0.916) | −0.053(0.224) | 0.045(0.298) | −0.020(0.652) |
| Systolic BP | 0.091 (0.034) | 0.055(0.206) | −0.004 (0.926) | −0.060(0.167) |
| Diastolic BP | 0.067 (0.123) | 0.016(0.719) | 0.010 (0.817) | −0.014(0.745) |
| Serum TG | 0.009 (0.828) | −0.012(0.778) | 0.093 (0.031) | 0.037(0.397) |
| Serum TC | 0.036 (0.404) | 0.018(0.680) | 0.146 (0.001) | 0.070(0.105) |
| Serum HDL-c | 0.100 (0.020) | 0.076(0.082) | 0.021 (0.632) | 0.052(0.228) |
| Serum LDL-c | 0.019 (0.669) | 0.012(0.777) | 0.144 (0.001) | 0.070(0.107) |
| Atherogenic index (AI) | −0.059 (0.176) | −0.055(0.207) | 0.068 (0.115) | −0.002(0.955) |
| Serum glucose | 0.101 (0.019) | 0.000(0.994) | 0.099 (0.021) | 0.018(0.683) |
| Serum insulin | 0.052 (0.232) | 0.039(0.373) | 0.056 (0.189) | 0.063(0.147) |
| HOMA-IR | 0.067 (0.121) | 0.037(0.397) | 0.071 (0.098) | 0.061(0.162) |
| HOMA-β | 0.078(0.073) | 0.022(0.621) | 0.090(0.036) | 0.049(0.254) |
| QUICKI | −0.053 (0.220) | −0.022(0.611) | −0.067 (0.117) | −0.060(0.165) |
r1: correlation coefficient; r2: controlled for age, total calorie intake, physical activity level, medicine status, alcohol intake, smoking status; r3 controlled for age, total calorie intake, physical activity level, medicine status, alcohol intake, smoking status and menopausal staus; Statistical significance was set to p < 0.05.
To further identify the associations, we performed linear regression analysis and the findings are presented in Table 3. After all the confounding factors were controlled, serum L-carnitine level was found to be positively correlated with serum TG level, serum insulin level, HOMA-IR index, and negatively correlated with QUICKI index in males (p < 0.05 for all). In females, serum L-carnitine level was positively correlated with weight, BMI, WC, hip circumference, serum TC, glucose level, insulin levels, HOMA-IR index, HOMA-β index, and negatively correlated with QUICKI index (p < 0.05 for all). Serum TMAO level was not associated with any component of MS in either females or males.
Table 3.
Linear Regression analysis of serum L-carnitine, TMAO levels with metabolic syndrome related indexesa.
| Men (n = 536) | Women (n = 545) | |||||
|---|---|---|---|---|---|---|
| R2 | β* | P | R2 | β* | P | |
| L-CARNITINE (μmol/L) | ||||||
| Weight | 0.035 | 0.026 | 0.554 | 0.057 | 0.216 | 0.000 |
| BMI | 0.075 | 0.043 | 0.318 | 0.089 | 0.203 | 0.000 |
| Waist circumference | 0.138 | 0.030 | 0.459 | 0.132 | 0.155 | 0.001 |
| Hip circumference | 0.123 | 0.040 | 0.327 | 0.112 | 0.195 | 0.000 |
| Waist/hip ratio | 0.055 | 0.003 | 0.937 | 0.061 | 0.016 | 0.730 |
| Systolic BP | 0.041 | 0.033 | 0.446 | 0.080 | 0.040 | 0.388 |
| Diastolic BP | 0.107 | −0.019 | 0.645 | 0.042 | 0.039 | 0.405 |
| Serum TG | 0.164 | 0.130 | 0.001 | 0.108 | 0.040 | 0.406 |
| Serum TC | 0.115 | 0.068 | 0.104 | 0.117 | 0.095 | 0.035 |
| Serum HDL-c | 0.085 | −0.005 | 0.898 | 0.091 | 0.029 | 0.533 |
| Serum LDL-c | 0.090 | 0.017 | 0.692 | 0.106 | 0.064 | 0.161 |
| Atherogenic index (AI) | 0.154 | 0.021 | 0.603 | 0.095 | 0.032 | 0.481 |
| Serum glucose | 0.189 | −0.016 | 0.684 | 0.150 | 0.097 | 0.028 |
| Serum insulin | 0.290 | 0.096 | 0.010 | 0.180 | 0.140 | 0.001 |
| HOMA-IR | 0.307 | 0.087 | 0.018 | 0.190 | 0.146 | 0.001 |
| HOMA-β | 0.302 | 0.071 | 0.056 | 0.190 | 0.137 | 0.002 |
| QUICKI | 0.305 | −0.090 | 0.015 | 0.192 | −0.150 | 0.001 |
| TMAO (μmol/L) | ||||||
| Weight | 0.025 | −0.059 | 0.188 | 0.020 | 0.035 | 0.438 |
| BMI | 0.066 | −0.068 | 0.122 | 0.055 | −0.010 | 0.822 |
| Waist circumference | 0.140 | −0.052 | 0.216 | 0.113 | −0.009 | 0.843 |
| Hip circumference | 0.123 | −0.032 | 0.449 | 0.081 | 0.000 | 0.992 |
| Waist/hip ratio | 0.058 | −0.054 | 0.216 | 0.061 | −0.022 | 0.614 |
| Systolic BP | 0.043 | 0.053 | 0.236 | 0.080 | −0.059 | 0.183 |
| Diastolic BP | 0.107 | 0.013 | 0.753 | 0.041 | −0.014 | 0.763 |
| Serum TG | 0.147 | −0.013 | 0.760 | 0.106 | 0.038 | 0.383 |
| Serum TC | 0.111 | 0.019 | 0.658 | 0.113 | 0.069 | 0.112 |
| Serum HDL-c | 0.090 | 0.077 | 0.077 | 0.092 | 0.050 | 0.252 |
| Serum LDL-c | 0.090 | 0.014 | 0.754 | 0.107 | 0.067 | 0.121 |
| Atherogenic index (AI) | 0.156 | −0.053 | 0.206 | 0.093 | −0.001 | 0.973 |
| Serum glucose | 0.188 | 0.002 | 0.969 | 0.141 | 0.022 | 0.613 |
| Serum insulin | 0.282 | 0.034 | 0.883 | 0.168 | 0.065 | 0.119 |
| HOMA-IR | 0.300 | 0.032 | 0.398 | 0.176 | 0.063 | 0.129 |
| HOMA-β | 0.298 | 0.019 | 0.613 | 0.177 | 0.052 | 0.209 |
| QUICKI | 0.298 | −0.019 | 0.610 | 0.177 | −0.062 | 0.137 |
Models were multiple linear regression with statistical significant associations at p < 0.05. All analyses were controlled for age, total calorie intake, physical activity level, medicine status, alcohol intake, smoking status, and menopausal status. β, Unstandardized Beta;
standardized coefficient; R2, Adjusted R square.
Correlation Between Serum TMAO, L-Carnitine Levels, and MS Related Indexes in Subjects With Normal Serum Glucose Level
The correlations between serum L-carnitine and TMAO levels with MS-related indexes in subjects with normal glucose levels are shown in Table 4. In males, serum L-carnitine level was positively correlated with serum TG level (r = 0.126, p < 0.05), serum insulin level (r = 0.121, p < 0.05), HOMA-IR (r = 0.114, p < 0.05), and negatively correlated with QUICKI index (r = −0.113, p < 0.05). In females, serum L-carnitine level was positively correlated with weight (r = 0.164, P < 0.000), BMI (r = 0.157, P < 0.01), WC (r = 0.123, P < 0.01), hip circumference (r = 0.147, P < 0.01), serum TC (r = 0.093, p < 0.05), glucose levels (r = 0.092, p < 0.05), insulin levels (r = 0.139, p < 0.01), HOMA-IR index (r = 0.145, p < 0.01), HOMA-β index (r = 0.131, p < 0.01), and negatively correlated with QUICKI index (r = −0.146, p < 0.01). No significant relationships were found between serum TMAO level and MS related indexes.
Table 4.
Partial correlations between serum L-Carnitine, TMAO levels with components of MS in females and males with normal serum glucose level.
| Male (n = 400) | Female (n = 465) | |||
|---|---|---|---|---|
| r1(P) | r2(P) | r1(P) | r3(P) | |
| L-CARNITINE (μmol/L) | ||||
| Weight | 0.030 (0.549) | 0.017 (0.736) | 0.174 (0.000) | 0.164 (0.000) |
| BMI | 0.053 (0.287) | 0.033 (0.509) | 0.210 (0.000) | 0.157 (0.001) |
| Waist circumference | 0.057 (0.254) | 0.032 (0.522) | 0.223 (0.000) | 0.123 (0.009) |
| Hip circumference | 0.050 (0.316) | 0.025 (0.619) | 0.224 (0.000) | 0.147 (0.002) |
| Waist/hip ratio | 0.046 (0.360) | 0.033 (0.518) | 0.097 (0.037) | 0.017 (0.712) |
| Systolic BP | 0.067 (0.183) | 0.055 (0.276) | 0.072 (0.121) | 0.007 (0.882) |
| Diastolic BP | 0.027 (0.588) | 0.003 (0.956) | 0.052 (0.267) | 0.002 (0.961) |
| Serum TG | 0.149 (0.003) | 0.126 (0.013) | 0.106 (0.023) | 0.029 (0.543) |
| Serum TC | 0.104 (0.037) | 0.072 (0.154) | 0.201 (0.000) | 0.093 (0.047) |
| Serum HDL-c | −0.034 (0.498) | −0.038 (0.458) | −0.051 (0.276) | −0.006 (0.904) |
| Serum LDL-c | 0.068 (0.175) | 0.040 (0.435) | 0.191 (0.000) | 0.078 (0.98) |
| Atherogenic index (AI) | 0.076 (0.130) | 0.051 (0.310) | 0.149 (0.001) | 0.053 (0.257) |
| Serum glucose | −0.016 (0.746) | −0.040 (0.427) | 0.219 (0.000) | 0.092 (0.049) |
| Serum insulin | 0.138 (0.006) | 0.121 (0.016) | 0.123 (0.008) | 0.139 (0.003) |
| HOMA-IR | 0.134 (0.007) | 0.114 (0.024) | 0.149 (0.001) | 0.145 (0.002) |
| HOMA-β | 0.119 (0.017) | 0.093 (0.066) | 0.182 (0.000) | 0.131 (0.005) |
| QUICKI | −0.134 (0.007) | −0.113 (0.026) | −0.147 (0.002) | −0.146 (0.002) |
| TMAO (μmol/L) | ||||
| Weight | −0.073 (0.147) | −0.072 (0.157) | 0.049 (0.289) | 0.039 (0.410) |
| BMI | −0.066 (0.190) | −0.084 (0.096) | 0.053 (0.254) | 0.011 (0.813) |
| Waist circumference | −0.022 (0.658) | −0.062 (0.223) | 0.077 (0.097) | −0.002 (0.964) |
| Hip circumference | −0.027 (0.587) | −0.053 (0.296) | 0.059 (0.203) | 0.004 (0.939) |
| Waist/hip ratio | 0.007 (0.890) | −0.036 (0.474) | 0.054 (0.250) | −0.014 (0.773) |
| Systolic BP | 0.072 (0.150) | 0.063 (0.211) | 0.007 (0.874) | −0.051 (0.278) |
| Diastolic BP | 0.044 (0.380) | 0.015 (0.760) | 0.024 (0.603) | −0.003 (0.948) |
| Serum TG | 0.020 (0.696) | 0.031 (0.540) | 0.129 (0.005) | 0.072 (0.127) |
| Serum TC | 0.076 (0.130) | 0.063 (0.216) | 0.177 (0.000) | 0.085 (0.070) |
| Serum HDL-c | 0.106 (0.034) | 0.075 (0.140) | 0.012 (0.793) | 0.041 (0.380) |
| Serum LDL-c | 0.054 (0.285) | 0.042 (0.411) | 0.169 (0.000) | 0.083 (0.077) |
| Atherogenic index (AI) | −0.035 (0.480) | −0.025 (0.628) | 0.099 (0.033) | 0.023 (0.632) |
| Serum Glucose | −0.012 (0.812) | −0.052 (0.301) | 0.124 (0.007) | 0.029 (0.536) |
| Serum Insulin | −0.026 (0.604) | 0.000 (0.994) | 0.055 (0.240) | 0.072 (0.125) |
| HOMA-IR | −0.027 (0.593) | −0.006 (0.904) | 0.070 (0.131) | 0.072 (0.123) |
| HOMA-β | −0.030 (0.549) | −0.024 (0.633) | 0.095 (0.041) | 0.061 (0.194) |
| QUICKI | 0.031 (0.534) | 0.012 (0.819) | −0.064 (0.166) | −0.068 (0.144) |
r1: correlation coefficient; r2: controlled for age, total caloric intake, physical activity level, medicine status, alcohol intake, smoking status; r3 controlled for age, total calorie intake, physical activity level, medicine status, alcohol intake, smoking status and menopausal status; Statistical significance was set to p < 0.05.
Linear regression analysis was performed to further identify the correlations between serum L-carnitine, TMAO levels, and MS in subjects with normal serum glucose levels, and the findings are presented in Table 5. After all confounding factors were controlled, serum L-carnitine level was positively correlated with serum TG level, serum insulin level, HOMA-IR index and negatively correlated with QUICKI index in males (p < 0.05 for all). In females, serum L-carnitine level was positively correlated with weight, BMI, WC, hip circumference, serum TC, glucose levels, insulin levels, HOMA-IR index, HOMA-β index and negatively correlated with QUICKI index (p < 0.05 for all). Serum TMAO level was not associated with any component of the MS in both females and males.
Table 5.
Linear Regression analysis of serum L-carnitine, TMAO levels with MS related indexes in subjects with normal fasting glucose levelsa.
| Male (n = 400) | Female (n = 465) | |||||
|---|---|---|---|---|---|---|
| R2 | β* | P | R2 | β* | P | |
| L-CARNITINE (μmol/L) | ||||||
| Weight | 0.030 | 0.018 | 0.716 | 0.030 | 0.181 | 0.000 |
| BMI | 0.073 | 0.034 | 0.489 | 0.071 | 0.170 | 0.001 |
| Waist circumference | 0.143 | 0.031 | 0.505 | 0.129 | 0.128 | 0.009 |
| Hip circumference | 0.124 | 0.026 | 0.576 | 0.102 | 0.156 | 0.002 |
| Waist/hip ratio | 0.065 | 0.030 | 0.546 | 0.067 | 0.020 | 0.693 |
| Systolic BP | 0.018 | 0.048 | 0.338 | 0.049 | 0.007 | 0.893 |
| Diastolic BP | 0.106 | −0.001 | 0.978 | 0.028 | 0.003 | 0.960 |
| Serum TG | 0.181 | 0.114 | 0.014 | 0.112 | 0.030 | 0.543 |
| Serum TC | 0.152 | 0.071 | 0.128 | 0.130 | 0.096 | 0.047 |
| Serum HDL-c | 0.083 | −0.033 | 0.495 | 0.090 | −0.006 | 0.903 |
| Serum LDL-c | 0.121 | 0.041 | 0.386 | 0.112 | 0.082 | 0.094 |
| Atherogenic index (AI) | 0.182 | 0.048 | 0.296 | 0.106 | 0.055 | 0.258 |
| Serum glucose | 0.057 | −0.038 | 0.445 | 0.129 | 0.096 | 0.047 |
| Serum insulin | 0.278 | 0.104 | 0.016 | 0.150 | 0.143 | 0.003 |
| HOMA-IR | 0.277 | 0.098 | 0.023 | 0.151 | 0.149 | 0.002 |
| HOMA-β | 0.245 | 0.082 | 0.064 | 0.137 | 0.135 | 0.005 |
| QUICKI | 0.270 | −0.097 | 0.025 | 0.151 | −0.150 | 0.002 |
| TMAO (μmol/L) | ||||||
| Weight | 0.035 | −0.072 | 0.158 | 0.005 | 0.041 | 0.407 |
| BMI | 0.079 | −0.082 | 0.097 | 0.048 | 0.011 | 0.817 |
| Waist circumference | 0.146 | −0.058 | 0.225 | 0.116 | −0.003 | 0.956 |
| Hip circumference | 0.126 | −0.050 | 0.301 | 0.082 | 0.004 | 0.937 |
| Waist/hip ratio | 0.065 | −0.036 | 0.469 | 0.068 | −0.015 | 0.758 |
| Systolic BP | 0.019 | 0.060 | 0.241 | 0.050 | −0.051 | 0.294 |
| Diastolic BP | 0.106 | 0.012 | 0.799 | 0.029 | −0.002 | 0.970 |
| Serum TG | 0.169 | 0.028 | 0.554 | 0.113 | 0.070 | 0.135 |
| Serum TC | 0.151 | 0.062 | 0.195 | 0.127 | 0.085 | 0.069 |
| Serum HDL-c | 0.088 | 0.076 | 0.127 | 0.091 | 0.043 | 0.361 |
| Serum LDL-c | 0.121 | 0.042 | 0.383 | 0.112 | 0.081 | 0.084 |
| Atherogenic index (AI) | 0.180 | −0.022 | 0.633 | 0.102 | 0.020 | 0.679 |
| Serum glucose | 0.058 | −0.051 | 0.311 | 0.122 | 0.028 | 0.553 |
| Serum insulin | 0.267 | 0.000 | 0.994 | 0.139 | 0.071 | 0.125 |
| HOMA-IR | 0.268 | −0.005 | 0.907 | 0.137 | 0.071 | 0.124 |
| HOMA-β | 0.239 | −0.021 | 0.639 | 0.124 | 0.060 | 0.198 |
| QUICKI | 0.261 | 0.010 | 0.821 | 0.136 | −0.068 | 0.146 |
Models were multiple linear regression with statistical significant associations at p < 0.05. All analyses were controlled for age, total calorie intake, physical activity, BF%, medicine status, alcohol intake, smoking status and menopausal status. β, Unstandardized Beta;
standardized coefficient; R2, Adjusted R square.
Correlation Between Serum TMAO, L-Carnitine Levels, and MS Related Indexes in Subjects With Hyperglycemia
The correlations between serum L-carnitine and TMAO levels with MS related indexes in subjects with hyperglycemia are presented in Table 6. In males, serum L-carnitine level was positively correlated with serum TG level (r = 0.180, p < 0.05). No significant relationships were found between serum L-carnitine level and MS related indexes in females.
Table 6.
Partial correlations between serum L-carnitine, TMAO levels with components of MS in females and males with hyperglycemia.
| Male (n = 136) | Female (n = 79) | |||
|---|---|---|---|---|
| r1(P) | r2(P) | r1(P) | r3(P) | |
| L-CARNITINE (μmol/L) | ||||
| Weight | 0.058(0.510) | 0.051(0.564) | 0.193 (0.093) | 0.213(0.074) |
| BMI | 0.108(0.217) | 0.079(0.378) | 0.157 (0.174) | 0.155(0.197) |
| Waist circumference | 0.081(0.352) | 0.019(0.833) | 0.130(0.260) | 0.143(0.234) |
| Hip circumference | 0.160(0.066) | 0.093(0.295) | 0.210(0.066) | 0.197(0.099) |
| Waist/hip ratio | −0.113(0.196) | −0.126(0.157) | −0.41(0.724) | 0.005(0.966) |
| Systolic BP | 0.018(0.831) | −0.021(0.816) | 0.103(0.366) | 0.108(0.378) |
| Diastolic BP | −0.005(0.956) | −0.116(0.194) | 0.099(0.384) | 0.174(0.153) |
| Serum TG | 0.218(0.011) | 0.180(0.044) | 0.040 (0.726) | −0.005(0.965) |
| Serum TC | 0.067(0.440) | 0.105(0.244) | 0.030(0.794) | 0.094(0.444) |
| Serum HDL-c | 0.052(0.551) | 0.124(0.166) | 0.130(0.252) | 0.266(0.027) |
| Serum LDL-c | −0.045(0.601) | −0.004(0.965) | −0.041(0.718) | −0.010(0.934) |
| Atherogenic index (AI) | −0.016(0.849) | −0.052(0.561) | −0.101(0.377) | −0.161(0.186) |
| Serum glucose | −0.100(0.245) | −0.124(0.167) | −0.040(0.724) | −0.105(0.391) |
| Serum insulin | 0.138(0.109) | 0.046(0.610) | 0.084 (0.464) | −0.066(0.589) |
| HOMA-IR | 0.115(0.182) | 0.020(0.820) | 0.070(0.538) | −0.084(0.492) |
| HOMA-β | 0.085(0.324) | −0.010(0.912) | 0.056 (0.626) | −0.098(0.425) |
| QUICKI | −0.133(0.123) | −0.039(0.667) | −0.099(0.385) | 0.055(0.651) |
| TMAO (μmol/L) | ||||
| Weight | 0.014(0.871) | 0.003(0.970) | 0.022(0.851) | 0.005(0.969) |
| BMI | 0.044(0.612) | 0.001(0.995) | −0.116(0.315) | −0.122(0.311) |
| Waist circumference | 0.035(0.693) | −0.007(0.940) | −0.034(0.771) | −0.056(0.644) |
| Hip circumference | 0.109(0.213) | 0.044(0.619) | −0.025(0.831) | −0.029(0.813) |
| Waist/hip ratio | −0.127(0.144) | −0.097(0.297) | −0.051(0.659) | −0.089(0.461) |
| Systolic BP | 0.086(0.321) | 0.022(0.810) | −0.123(0.281) | −0.142(0.246) |
| Diastolic BP | 0.096(0.265) | −0.022(0.805) | −0.105(0.357) | −0.088(0.472) |
| Serum TG | −0.095(0.271) | −0.139(0.122) | −0.134(0.240) | −0.145(0.235) |
| Serum TC | −0.110(0.201) | −0.069(0.443) | −0.029(0.798) | 0.008(0.949) |
| Serum HDL-c | 0.079(0.360) | 0.096(0.287) | 0.085(0.454) | 0.137(0.262) |
| Serum LDL-c | −0.080(0.352) | −0.027(0.765) | −0.015(0.896) | −0.007(0.956) |
| Atherogenic index (AI) | −0.149(0.083) | −0.129(0.150) | −0.150(0.188) | −0.154(0.205) |
| Serum glucose | 0.153(0.075) | 0.088(0.328) | 0.074(0.519) | 0.075(0.540) |
| Serum insulin | 0.211(0.014) | 0.172(0.045) | 0.028(0.809) | 0.074(0.544) |
| HOMA-IR | 0.235(0.006) | 0.188(0.035) | 0.041(0.720) | 0.085(0.486) |
| HOMA-β | 0.252(0.003) | 0.197(0.027) | 0.053(0.642) | 0.092(0.452) |
| QUICKI | −0.221(0.010) | −0.175(0.049) | −0.044(0.699) | −0.092(0.450) |
r1: correlation coefficient; r2: controlled for age, total calorie intake, physical activity level, medicine status, alcohol intake, smoking status; r3 controlled for age, total calorie intake, physical activity level, medicine status, alcohol intake, smoking status and menopausal status; Statistical significance was set to p < 0.05.
Serum TMAO level was positively related with insulin levels (r = 0.172, p < 0.05), HOMA-IR index (r = 0.188, p < 0.05), HOMA-β index (r = 0.197, p < 0.05) and negatively correlated with QUICKI index (r = −0.175, p < 0.05. No significant relationships were found between serum TMAO level and MS related indexes in females.
Linear regression analysis was also performed to further identify the correlations between serum L-carnitine, TMAO levels, and MS in subjects with hyperglycemia, and the findings are presented in Table 7. In males, after all the confounding factors were controlled, serum L-carnitine level was positively correlated with serum TG level (p < 0.05). While serum TMAO level was positively related to serum insulin levels, HOMA-IR index and HOMA-β index, it was negatively correlated with QUICKI index (p < 0.05 for all). In females, neither serum L-carnitine nor TMAO levels were associated with any component of MS.
Table 7.
Linear regression analysis of serum L-carnitine, TMAO levels with metabolic syndrome related indexes in subjects with hyperglycemiaa.
| Men (n = 536) | Women (n = 545) | |||||
|---|---|---|---|---|---|---|
| R2 | β* | P | R2 | β* | P | |
| L-CARNITINE (μmol/L) | ||||||
| Weight | 0.010 | 0.066 | 0.477 | 0.112 | 0.233 | 0.065 |
| BMI | 0.009 | 0.098 | 0.291 | 0.072 | 0.169 | 0.190 |
| Waist circumference | 0.038 | 0.037 | 0.681 | −0.023 | 0.163 | 0.227 |
| Hip circumference | 0.061 | 0.114 | 0.205 | 0.034 | −0.028 | 0.813 |
| Waist/hip ratio | 0.004 | −0.127 | 0.172 | −0.030 | −0.090 | 0.461 |
| Rsystolic BP | -0.010 | −0.034 | 0.716 | 0.007 | 0.112 | 0.410 |
| Diastolic BP | 0.123 | −0.118 | 0.172 | −0.047 | 0.203 | 0.147 |
| Serum TG | 0.041 | 0.183 | 0.044 | 0.008 | −0.013 | 0.924 |
| Serum TC | 0.057 | 0.102 | 0.252 | 0.113 | 0.097 | 0.450 |
| Serum HDL-c | 0.089 | 0.003 | 0.180 | 0.061 | 0.288 | 0.031 |
| Serum LDL-c | 0.061 | −0.003 | 0.975 | 0.046 | −0.005 | 0.970 |
| Atherogenic index (AI) | 0.066 | −0.054 | 0.548 | −0.070 | −0.168 | 0.234 |
| Serum glucose | 0.126 | −0.117 | 0.175 | −0.035 | −0.114 | 0.411 |
| Serum insulin | 0.184 | 0.040 | 0.632 | 0.120 | −0.050 | 0.696 |
| HOMA-IR | 0.209 | 0.017 | 0.203 | 0.096 | −0.070 | 0.587 |
| HOMA-β | 0.223 | −0.011 | 0.895 | 0.069 | −0.087 | 0.508 |
| QUICKI | 0.218 | −0.035 | 0.668 | 0.114 | 0.041 | 0.748 |
| TMAO (μmol/L) | ||||||
| Weight | 0.006 | 0.005 | 0.960 | 0.066 | 0.010 | 0.931 |
| BMI | 0.000 | 0.002 | 0.981 | 0.062 | −0.116 | 0.324 |
| Waist circumference | 0.037 | −0.005 | 0.955 | −0.043 | −0.054 | 0.661 |
| Hip circumference | 0.051 | 0.048 | 0.02 | 0.021 | −0.026 | 0.827 |
| Waist/hip ratio | -0.001 | −0.102 | 0.282 | −0.044 | −0.088 | 0.457 |
| Systolic BP | -0.011 | 0.021 | 0.826 | 0.020 | −0.149 | 0.218 |
| Diastolic BP | 0.110 | −0.024 | 0.785 | −0.070 | −0.105 | 0.405 |
| Serum TG | 0.029 | −0.148 | 0.114 | 0.027 | −0.134 | 0.265 |
| Serum TC | 0.052 | −0.074 | 0.418 | 0.105 | −0.008 | 0.946 |
| Serum HDL-c | 0.084 | 0.093 | 0.302 | 0.007 | 0.114 | 0.349 |
| Serum LDL-c | 0.061 | −0.029 | 0.753 | 0.046 | −0.018 | 0.882 |
| Atherogenic index (AI) | 0.079 | −0.132 | 0.145 | −0.071 | −0.145 | 0.248 |
| Serum glucose | 0.121 | 0.092 | 0.299 | −0.039 | 0.080 | 0.518 |
| Serum insulin | 0.206 | 0.161 | 0.047 | 0.127 | 0.095 | 0.402 |
| HOMA-IR | 0.237 | 0.175 | 0.036 | 0.104 | 0.106 | 0.358 |
| HOMA-β | 0.253 | 0.183 | 0.027 | 0.076 | 0.113 | 0.335 |
| QUICKI | 0.240 | −0.162 | 0.041 | 0.125 | −0.111 | 0.331 |
Models were multiple linear regression with statistical significant associations at p < 0.05. All analyses were controlled for age, total calorie intake, physical activity level, BF%, medicine status, alcohol intake, smoking status and menopausal status. β, Unstandardized Beta;
standardized coefficient; R2, Adjusted R square.
Discussion
In this relatively large population-based cross-sectional study, we investigated the associations of serum L-carnitine and TMAO levels with MS related indexes, including obesity, blood pressure, serum lipids, serum glucose, and IR-related indexes after controlling for major confounding factors. Significant positive associations were identified in a number of physiological and pathological conditions. Firstly, we discovered that there was a positive correlation between serum L-carnitine and TMAO levels with MS profiles based on serum glucose status. Moreover, we revealed that some associations are gender specific. Briefly, serum L-carnitine level was positively correlated with serum TG level, serum insulin level, IR in males with normal fasting glucose levels and positively correlated with only serum TG level in those with hyperglycemia. In females, positive correlations were found between serum L-carnitine level and obesity, serum TC level, serum glucose level, serum insulin levels, IR in females with normal fasting glucose levels, while none was found in those with hyperglycemia. Serum TMAO level was positively correlated with serum insulin level and IR in males with hyperglycemia only.
The present study has several strengths. Firstly, a broad involvement of MS related components. MS is comprised of multiple risk factors for T2D and CVD, including obesity, hypertension, dyslipidemia, hyperglycemia and IR with obesity and IR as the source of pathogenesis (28). In the present study, all five categories of MS related components (obesity, blood pressure, serum lipid levels, fasting glucose, and IR) were systematically studied. Due to the relationship between MS and CVD, atherogenic index was calculated and included in the analysis as well (29). In addition, the systematic control of major confounding factors makes the findings more reliable. In a large population-based study, identifying the primary confounding factors and properly controlling their effects are essential steps for obtaining reliable results. MS is a complicated pathological condition with various factors involved (30), especially age and gender (7, 30). Calorie intake and physical activity level, major factors in keeping the balance of energy obtained and consumed, can strongly influence hypertension (31), glucose and lipid metabolism (7), and insulin sensitivity (32). Moreover, medicine status, alcohol intake, smoking status, and menopausal status were taken into consideration in analyses. Medication use, alcohol consumption, and smoking status are recognized as potential covariates that may influence energy intake, hypertension risk, and insulin sensitivity (33, 34). Menopause is related to changes in sex hormones that may affect MS profiles in females (35). In this study, all these factors that can potentially affect the relationships between serum L-carnitine and TMAO levels with MS profiles were identified and controlled.
The most notable finding in the present study is the positive correlation of serum L-carnitine levels and TMAO levels with MS profiles. Moreover, the significant correlations are gender specific and depend on serum glucose status. L-carnitine is an important metabolite involved in fatty acid metabolism and has been used as an ergogenic aid in treatment of weight loss (36). While, herein, we found unfavorable associations between serum L-carnitine levels with MS profiles. In subjects with normal fasting glucose levels, serum L-carnitine was found to be positively correlated with serum TG level, serum insulin level, IR in males and with obesity measurements, serum TC level, serum glucose levels, serum insulin levels, and IR in females, while in subjects with hyperglycemia there was only positive correlation between serum L-carnitine and TG levels in males. Association studies regarding serum L-carnitine levels and MS are rare. To date, only one cross-sectional study examined the correlations between serum L-carnitine levels and MS profile in 118 healthy women with singleton term pregnancy (16). The study identified significant negative correlations between serum L-carnitine with pre-pregnancy body weight, BMI and serum TG levels (16). Due to the unusual metabolic and energy status during pregnancy, the difference is hard to explain and may not be contradictory. However, numerous interventional studies have been performed and have shown weight loss and anti-hyperlipidemia effect of dietary L-carnitine supplementation in both humans and animals (36). Dietary treatment with L-carnitine also alleviates IR in high fructose-fed rodents (15). These studies show results apparently inconsistent with ours. While L-carnitine is not only acquired through dietary intake, it is also synthesized de novo from L-lysine and L-methionine (36). For this reason, L-carnitine is not recognized as an essential dietary nutrient and no recommended nutrient intakes (RNI) are set (37). Moreover, L-carnitine supplementation and L-carnitine acquired through diet also represent two significantly different situations. Getting more L-carnitine through diet alone means also taking in more meat protein and fat, that carry a negative impact on health, while, L-carnitine supplementation avoids these downsides. Hence, the correlations between dietary L-carnitine supplementation and serum L-carnitine levels with MS may be different and requires further investigation. In addition, L-carnitine is reported to decrease hypertension (38). However, no significant correlations were found between serum L-carnitine level and blood pressure in our study.
Serum TMAO level was only positively correlated with serum insulin level and IR in hyperglycemic males in our study. TMAO is a gut microbiota generated metabolite which can be generated from dietary L-carnitine or other TMA containing components in food. Recent studies reported that elevated TMAO levels were observed in various metabolic diseases, including patients with CVD (39), T2DM (40) or chronic kidney diseases (41) and rodents with obesity (42). Cross-sectional studies regarding the relationship between serum TMAO level and MS profiles are rare. Chen et al. reported serum TMAO level positively associated with serum TG, TC, LDL-c levels and development of NAFLD in 1,628 community-based adults (43). A recent cross-sectional study by Latkovskis et al. indicated that serum TMAO level was significantly related with IR in 300 patients with increased CVD risk (13). All these reports indicate that TMAO plays a potential role in the progression of various chronic diseases. Our previous study in male mice proved that supplementary dietary TMAO exacerbated IR in high fat diet induced obese mice by inducing chronic inflammation in adipose tissue and blocking insulin signaling pathway conduction, while it has no effect on normal mice (12). These findings are consistent with the observations of our current study. No correlations were identified between serum TMAO levels and MS profiles in subjects with normal serum glucose level, while significant associations were identified between serum TMAO levels and IR in hyperglycemia males. Our findings suggested that potentially harmful effects of TMAO may be more pronounced in metabolically abnormal subjects, and may not be evident or easily detected in milder cases of MS or potentially earlier on in the condition onset. Moreover, although studies in rodents reported that serum TMAO levels were elevated in obese subjects (43), we did not find any notable correlations between serum TMAO level and obesity measures. This suggests that other complex factors impacting on serum TMAO level may be at play, which would require further studies.
Some limitations should be acknowledged here. First, this study is of cross-sectional design and we could not build causal relationships between serum L-carnitine or TMAO levels and components of MS. Further longitudinal or interventional studies are warranted. Secondly, the number of subjects in hyperglycemia groups are limited due to the composition of our cohort and difficulty in obtaining essential data. A larger study is needed to confirm the significant relationships between serum L-carnitine or TMAO levels and major outcomes. Lastly, although multiple factors were systematically controlled in our analysis, genetics or unknown residual factors could not be completely ruled out but might be of significance in reconciling our findings with those of others.
Conclusion
In conclusion, in general Newfoundland population, we provide solid evidence for the first time that serum L-carnitine level is significantly associated with an unfavorable MS profile, mainly serum TG levels, serum insulin level, IR in male subjects with normal serum glucose level and obesity, serum TC level, serum glucose level, serum insulin levels, and IR in females with normal serum glucose level. Serum TMAO level was positively associated with IR related indexes in hyperglycemic males. The totality of these unfavorable relationships were independent of age, total calorie intake, physical activity level, medication use, smoking status, alcohol consumption, and menopausal status. Our findings reveal novel insights into the relationships between serum TMAO and its related metabolic precursors in human health.
Data Availability
All datasets generated for this study are included in the manuscript and/or the supplementary files.
Author Contributions
GS and XG conceived and designed the experiments. XG and ER performed the experiments. XG and YT analyzed the data. XG draft the paper which was reviewed and modified by ER, HZ, and GS. All authors have read and approved the final manuscript.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
We would like to express our appreciations to all the volunteers who participated in the study.
Footnotes
Funding. The study was funded by a Canadian Institutes of Health Research (CIHR) (operating grant: MOP192552). XG was supported by the China Scholarship Council (No. [2014]3026).
References
- 1.Ufnal M, Zadlo A, Ostaszewski R. TMAO: a small molecule of great expectations. Nutrition. (2015) 31:1317–23. 10.1016/j.nut.2015.05.006 [DOI] [PubMed] [Google Scholar]
- 2.NowiŃski A, Ufnal M. Trimethylamine N-oxide: a harmful, protective or diagnostic marker in lifestyle diseases? Nutrition. (2018) 46:7–12. 10.1016/j.nut.2017.08.001 [DOI] [PubMed] [Google Scholar]
- 3.Fielding R, Riede L, Lugo JP, Bellamine A. L-carnitine supplementation in recovery after exercise. Nutrients. (2018) 10:349. 10.3390/nu10030349 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. (2013) 19:576–85. 10.1038/nm.3145 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. (2005) 365:560–77. 10.1016/S0140-6736(05)66378-7 [DOI] [PubMed] [Google Scholar]
- 6.Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. (2014) 2014:943162. 10.1155/2014/943162 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
- 7.Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The metabolic syndrome. Endocr Rev. (2008) 29:777–822. 10.4319/lo.1997.42.2.0250 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. (2011) 472:57–63. 10.1038/nature09922 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Elko R, Angela LS, Wang X, Miriam H, Andreas P, Heinzmann SS, et al. Relationship of Serum Trimethylamine N-Oxide (TMAO) Levels with early Atherosclerosis in Humans. Sci Rep. (2016) 6:26745 10.1038/srep26745 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Tang WHW, Wang Z, Li XS, Fan Y, Li DS, Wu Y, et al. Increased Trimethylamine N-oxide (TMAO) portends high mortality risk independent of glycemic control in patients with type 2 diabetes mellitus. Clin Chem. (2017) 63:297 10.1373/clinchem.2016.263640 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Gao X, Liu X, Xu J, Xue C, Xue Y, Wang Y. Dietary trimethylamine N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet. J Biosci Bioeng. (2014) 118:476–81. 10.1016/j.jbiosc.2014.03.001 [DOI] [PubMed] [Google Scholar]
- 12.Latkovskis G, Mazule M, Bondare L, Racicka A, Makarova E, Hartmane D, et al. Trimethylamine-N-oxide levels are associated with increased insulin resistance. Eur Heart J. (2017) 38:5331 10.1093/eurheartj/ehx493.P5331 [DOI] [Google Scholar]
- 13.Vallance HD, Koochin A, Branov J. Marked elevation in plasma trimethylamine-N-oxide (TMAO) in patients with mitochondrial disorders treated with orall-carnitine. Mol Genet Metab. (2018) 15:130–3. 10.1016/j.ymgmr.2018.04.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Shakeri A, Tabibi H, Ossareh S. Effects of L-carnitine supplementation on serum lipids and apoproteins in hemodialysis patients with Lp(a) hyperlipoproteinemia. J Mol Biol. (2007) 241:620–1. 10.1006/jmbi.1994.1535 [DOI] [Google Scholar]
- 15.Panchal SK, Poudyal H, Ward LC, Waanders J, Brown L. Modulation of tissue fatty acids by L-carnitine attenuates metabolic syndrome in diet-induced obese rats. Food Funct. (2015) 6:2496–506. 10.1039/c5fo00480b [DOI] [PubMed] [Google Scholar]
- 16.Tipiakbas P, Arioz DT, Kanatpektas M, Koken T, Koken G, Yilmazer M. Lowered serum total L-carnitine levels are associated with obesity at term pregnancy. J Mater Fetal Med. (2013) 26:1479–83. 10.3109/14767058.2013.789847 [DOI] [PubMed] [Google Scholar]
- 17.Samimi M, Jamilian M, Afshar EF, Rahimi M, Tajbakhsh B, Asemi Z. Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol. (2016) 84:851–7. 10.1111/cen.13003 [DOI] [PubMed] [Google Scholar]
- 18.Gao X, Wang Y, Edward R, Pardis P, Yi Y, Wayne G, et al. Higher dietary choline and betaine intakes are associated with better body composition in the adult population of Newfoundland, Canada. PLoS ONE. (2016) 11:e0155403. 10.1371/journal.pone.0155403 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Wang Y, Gao X, Pedram P, Shahidi M, Du J, Yi Y, et al. Significant beneficial association of high dietary selenium intake with reduced body fat in the CODING study. Nutrients. (2016) 8:24. 10.3390/nu8010024 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Shea JL, King MTC, Yi Y, Gulliver W, Sun G. Body fat percentage is associated with cardiometabolic dysregulation in BMI-defined normal weight subjects. Nutr Metab Cardiovasc. (2012) 22:741–7. 10.1016/j.numecd.2010.11.009 [DOI] [PubMed] [Google Scholar]
- 21.Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr. (1982) 36:936–42. 10.1093/ajcn/36.5.936 [DOI] [PubMed] [Google Scholar]
- 22.Wang Y, Lin M, Gao X, Pedram P, Du J, Vikram C, et al. High dietary selenium intake is associated with less insulin resistance in the Newfoundland population. PLoS ONE. (2017) 12:e0174149. 10.1371/journal.pone.0174149 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Ulbricht TLV, Southgate DAT. Coronary heart disease: seven dietary factors. Lancet. (1991) 338:985–92. 10.1016/0140-6736(91)91846-M [DOI] [PubMed] [Google Scholar]
- 24.Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. (1985) 28:412. 10.1007/BF00280883 [DOI] [PubMed] [Google Scholar]
- 25.Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocr Metab. (2000) 85:2402. 10.1210/jcem.85.7.6661 [DOI] [PubMed] [Google Scholar]
- 26.Gao X, Randell E, Zhou H, Sun G. Higher serum choline and betaine levels are associated with better body composition in male but not female population. PLoS ONE. (2018) 13:e0193114 10.1371/journal.pone.0193114 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Ecar E, Huzmeli C, Guven O. Frequency of metabolic syndrome among hemodialysis patients according to NCEP-ATP III and IDF definitions. Renal Failure. (2009) 31:221 10.1080/08860220802669883 [DOI] [PubMed] [Google Scholar]
- 28.Alberti KG, Zimmet P, Shaw J. The metabolic syndrome–a new worldwide definition. Lancet. (2005) 366:1059–62. 10.1016/S0140-6736(05)67402-8 [DOI] [PubMed] [Google Scholar]
- 29.Bellis A, Trimarco B. Pharmacological approach to cardiovascular risk in metabolic syndrome. J Cardiovasc Med. (2013) 14:403–9. 10.2459/JCM.0b013e32835dbd0d [DOI] [PubMed] [Google Scholar]
- 30.O'Neill S, O'Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev. (2015) 16:1–12. 10.1111/obr.12229 [DOI] [PubMed] [Google Scholar]
- 31.Schmieder RE, Schneider MP. Guidelines for management of arterial hypertension. Der Nephrologe. (2007) 2:441–7. 10.1007/s11560-007-0116-9 [DOI] [Google Scholar]
- 32.Yanai H, Adachi H, Masui Y, Katsuyama H, Kawaguchi A, Hakoshima M, et al. Exercise therapy for patients with type 2 diabetes: a narrative review. J Clin Med Res. (2018) 10:365–9. 10.14740/jocmr3382w [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Chiolero A, Faeh D, Paccaud F, Cornuz J, Chiolero A, Cornuz J. Consequences of smoking for body weight, body fat distribution, and insulin resistance. Am J Clin Nutr. (2008) 87:801–9. 10.1354/vp.44-6-885 [DOI] [PubMed] [Google Scholar]
- 34.Kiechl S, Willeit J, Poewe W, Egger G, Oberhollenzer F, Muggeo M, et al. Insulin sensitivity and regular alcohol consumption: large, prospective, cross sectional population study (Bruneck study). BMJ Brit Med J. (1996) 313:1040–4. 10.1136/bmj.313.7064.1040 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Meirelles RM. Menopause and metabolic syndrome. Arq Bras Endocrinol Metabol. (2014) 58:91–6. 10.1590/0004-2730000002909 [DOI] [PubMed] [Google Scholar]
- 36.Cha YS. Effects of L-carnitine on obesity, diabetes, and as an ergogenic aid. Asia Pac J Clin Nutr. (2008) 17:306–8. 10.6133/apjcn.2008.17.s1.75 [DOI] [PubMed] [Google Scholar]
- 37.Jacob C, Belleville F. L-carnitine: metabolism, functions and value in pathology. Pathol Biol. (1992) 40:910. [PubMed] [Google Scholar]
- 38.Clouatre DL, Bell SJ. Is L-Carnitine the Link between Red Meat and Heart Disease? J Nutr Food Sci. (2013) 3:e119 10.4172/2155-9600.1000e119 [DOI] [Google Scholar]
- 39.Nathalie B, Williams PT, Regina L, Nastaran F, Alyssa G, Li X, et al. Diets high in resistant starch increase plasma levels of trimethylamine-N-oxide, a gut microbiome metabolite associated with CVD risk. Brit J Nutr. (2016) 116:2020–9. 10.1017/S0007114516004165 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Dambrova M, Latkovskis G, Kuka J, Strele I, Konrade I, Grinberga S, et al. Diabetes is associated with higher trimethylamine N-oxide plasma levels. Exp Clin Endocrinol Diabetes. (2016) 124:251–6. 10.1055/s-0035-1569330 [DOI] [PubMed] [Google Scholar]
- 41.Missailidis C, Hällqvist J, Qureshi AR, Barany P, Heimbürger O, Lindholm B, et al. Serum trimethylamine-N-oxide is strongly related to renal function and predicts outcome in chronic kidney disease. PLoS ONE. (2016) 11:e0141738. 10.1371/journal.pone.0141738 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Chen K, Zheng X, Feng M, Li D, Zhang H. Gut Microbiota-Dependent Metabolite trimethylamine N-oxide contributes to cardiac dysfunction in western diet-induced obese mice. Front Physiol. (2017) 8:139. 10.3389/fphys.2017.00139 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Chen YM, Liu Y, Zhou RF, Chen XL, Wang C, Tan XY, et al. Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. Sci Rep. (2016) 6:19076. 10.1038/srep19076 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
All datasets generated for this study are included in the manuscript and/or the supplementary files.